CORO2B

Across TCGA pan-cancer cohorts, CORO2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CORO2B data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CORO2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CORO2B expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, CCRCC, and UCEC are the cancer types where CORO2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.613	0.442	.010	12	view →
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	12	view →
UCEC	DFS	Median	II,III,IV	0.536	0.880	.044	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CORO2B–GBM (OS)

Open the GBM breakdown →